Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
and strength and depth in oncology
Appendix
Innovation: Clinical trials
References
Abbreviations
Selected assets, nearly all with exclusivity into 2030+
Solid Tumors
Hematology
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Kisqali®
HR+/HER2- BC (adj)
Ph3 NATALEE readout event-
driven, expected 2023
2023
Canakinumab
NSCLC adjuvant
Ph3 CANOPY-A did not meet primary
endpoint
ScemblixⓇ
(asciminib)
Iptacopan²
CML 3L
CML 1L
PNH
EU Approval
Ph3 ongoing
2025
Primary endpoint met (Ph3
2023
APPLY-PNH); readout in 2022
Pluvicto™
mCRPC post-taxane
US approved
(Ph3 APPOINT-PNH)
mCRPC pre-taxane
Ph3 PSMAfore readout
2023
aHUS
Ph3 ongoing
2025
event-driven, end 20221
Sabatolimab
HR-MDS
Ph3 STIMULUS-MDS-2 ongoing
2024
mHSPC
Ph3 PSMAddition ongoing
2024
JDQ443
2/3L NSCLC (mono)
Ph3 ongoing
2024
AML
Ph2 STIMULUS-AML-1 ongoing
2026+
KRAS inhibitor
NSCLC (Combo)
Ph2 ongoing
2026+
TNO155
YTB323
CD19 CAR-T
Non-Hodgkin's
Lymphoma
Plans under review
20254
SHP2 inhibitor
Solid tumors: multiple combinations being explored in ongoing trials
PHE885
Tislelizumab²
2L esophageal cancer
NSCLC
Other indications
Ociperlimab²
NSCLC
TIGIT mab
Other indications
Submitted in EU
Submitted in EU
BCMA CART-T
Multiple
myeloma
Ph2 ongoing
2025
Ongoing trials
Ph3 ongoing³
Ongoing trials; additional
Ph3 study initiation H2 2022
Unprobabilized peak sales (USD): <1bn .. 1-2bn
... >2bn
'Bold Bets'
NIS793 (1L mPDAC: Ph3 ongoing, 1L metastatic colorectal cancer: Ph2 ongoing)
1. Could move to early 2023.
2. Peak sales potential based on all studied indications; Novartis territories. 3. Active trials are being conducted by BeiGene, option deal. 4. Development strategy being updated.
35 Investor Relations | Q3 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation